Hornbeck Offshore Services LLC

A Perfect Storm of Operational Challenges
Hornbeck Offshore Services LLC (Hornbeck) is a leading supplier of marine transportation services, including supply vessels, tankers, and barges, primarily in the Gulf of Mexico and Latin America. Headquartered in Louisiana with 1,200 employees, the company provides innovative, technologically-advanced solutions to meet the increasingly more complex drilling and vessel needs of the deep-water and ultra-deep-water energy industry.

REVA Medical Inc.

REVA Medical Inc. (REVA), a medical-device manufacturer, previously specialized in blood-vessel stents. The San Diego-based company produced these products for heart patients in European clinical trials. Unlike metal stents, REVA’s polymer-based stents gradually dissolved in the body, reducing inflammation and lowering risks of long-term complications once blood vessels healed. Despite the advantages of

Agera Energy LLC

Headquartered in New York, Agera Energy LLC (Agera), provided electricity and natural gas to commercial, industrial, and residential customers. The company, an alternative to the local utility, provided electricity and natural gas more customized to their users’ specific needs. By offering customers fixed-price contracts (as opposed to more flexible variable-price contracts), the company

Gawker Media LLC

Founded in 2003, Gawker Media LLC (Gawker) operated an online media company and blog network, serving as the parent company of several weblogs and subsites including: Gawker.com, Deadspin, Lifehacker, Gizmodo, Kotaku, Jalopnik, and Jezebel. Known for its brashness, and widely regarded as a go-to site for celebrity and entertainment gossip, Gawker.com routinely courted

Dendreon Corporation

Bolstered by their laboratory research on cell therapy remedies performed at Stanford University School of Medicine, Edgar Engleman and Samuel Strober started Dendreon Corporation (Dendreon). The biopharmaceutical company based in Seattle, Washington received initial funding from Health Care Ventures and entered the market in 1992. Early clinical results for Provenge, a cell-based cancer